Archive: Company News
Company News: Curetis Provides Business and Financial Update for the First Quarter 2017
– First quarter 2017 revenue increases 2.6-fold year over year
– Successful completion of CE performance evaluation study and launch of Unyvero IAI Intra-Abdominal Infections (IAI) Cartridge
– Incorporation of wholly-owned subsidiary Ares Genetics to accelerate commercialization of GEAR database
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the first quarter ended March 31, 2017, and provided details on its outlook for the remainder of the year.
Company News: Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017
– Phase I/II trial shows significant responses of HPV16-positive patients with late-stage cervical cancer
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that an update of the results of a company-sponsored clinical Phase I/II trial in late-stage cervical cancer patients (ISA101-CervISA) will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017, Chicago, IL, USA).
Company News: Curetis to Hold Annual General Shareholders’ Meeting on June 23, 2017
– Company nominates Dr Nils Clausnitzer for election into its Supervisory Board
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today published the invitation to its annual general shareholders’ meeting (“AGM”).
Company News: Recent Data on Curetis’ Unyvero ITI Application Demonstrate its Clinical and Health Economic Benefits
– Several ECCMID 2017 presentations highlight advantages of rapid time to result with Unyvero ITI in Prosthetic Joint Infections
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the recent presentation of new data demonstrating the clinical and health economic benefits of using the Company’s Unyvero ITI (Implant and Tissue Infections) Application for the diagnosis of prosthetic joint infections. Data were presented during this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID, April 22-25, 2017, Vienna/Austria).